A Phase 1 interventional study of saxagliptin and metformin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-08.
Sponsored by AstraZeneca · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 59th largest by enrollment, is one of 6 that started in 2010, is one of 14 in phase 1, and was the 24th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 4 · Phase 3 28 · Phase 4 25
First in 2003; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 138 across the 74 interventional studies. Of the 64 that completed or were terminated, 47 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 74 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 239th largest by enrollment of the 280 interventional ones that give a count, is one of 42 that started in 2010, is one of 86 in phase 1, and was the 153rd registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing saxagliptin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
To demonstrate bioequivalence of a 2.5 mg saxagliptin/850 mg metformin fixed dose combination (FDC) tablet relative to the 2.5 mg saxagliptin tablet and 850 mg metformin (Glucophage Marketed by Merck-Serono) tablet co-administered to healthy subjects in the fasted and fed condition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition.
Drug: saxagliptin · Drug: metformin
A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition.
Drug: saxagliptin + metformin (FDC tablet)
A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fed condition.
Drug: saxagliptin · Drug: metformin
A single oral dose of 2.5-mg saxagliptin/850-mg metformin FDC administered in the fed condition.
Drug: saxagliptin + metformin (FDC tablet)
Tablets, Oral, 2.5 mg, once daily, single dose
Also known as: Onglyza
Tablets, Oral, 850 mg, once daily, single dose
Also known as: Glucophage
Drug pages: Saxagliptin · Metformin
Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Saxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Metformin PK Parameter AUC(0-inf)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Metformin PK Parameter Cmax
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
5-hydroxy Saxagliptin PK Parameter AUC(0-inf)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
5-hydroxy Saxagliptin PK Parameter Cmax
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t])
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-t\] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Safety: Adverse Events (AEs), Discontinuations Due to AEs, Deaths, and Serious AEs (SAEs).
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
Time frame: AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).
Safety: Clinically Significant Laboratory, Vital Sign, Physical Examination, and/or 12-Lead Electrocardiogram (ECG) Abnormalities
Abnormalities that were considered clinically significant and/or reported as an AE by the investigator.
Time frame: From Day 1/Period 1 to study discharge or premature discontinuation. Duration of study was approximately 45 days (including screening).
Saxagliptin PK Parameter AUC(0-t)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Saxagliptin PK Parameter T1/2
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Saxagliptin PK Parameter Tmax
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Metformin PK Parameter AUC(0-t)
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Metformin PK Parameter T1/2
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Metformin PK Parameter Tmax
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
Time frame: Periods 1, 2, 3, & 4: pre-dosing, 15, 30, 45 mins & 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 & 48 hrs post-dosing
Participants (N = 24) who met all of the inclusion and none of the exclusion criteria were recruited from a single site in the United States.
| Milestone | Treatment Sequence ADBC | Treatment Sequence BACD | Treatment Sequence CBDA | Treatment Sequence DCAB |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ADBC | Treatment Sequence BACD | Treatment Sequence CBDA | Treatment Sequence DCAB |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence ADBC | Treatment Sequence BACD | Treatment Sequence CBDA | Treatment Sequence DCAB |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 5 | 6 | 6 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Milestone | Treatment Sequence ADBC | Treatment Sequence BACD | Treatment Sequence CBDA | Treatment Sequence DCAB |
|---|---|---|---|---|
| Started | 6 | 5 | 6 | 6 |
| Completed | 6 | 5 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
| ng*hr/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) | 49.23 ± 18.52 | 49.94 ± 19.72 | 52.50 ± 17.95 | 53.15 ± 17.81 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
| ng*hr/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| 5-hydroxy Saxagliptin PK Parameter AUC(0-inf) | 118.58 ± 24.08 | 119.54 ± 21.16 | 121.99 ± 25.42 | 125.54 ± 24.82 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
| ng/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| 5-hydroxy Saxagliptin PK Parameter Cmax | 16.83 ± 32.95 | 16.72 ± 32.92 | 17.35 ± 32.95 | 18.59 ± 30.78 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
| ng/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Saxagliptin PK Parameter Observed Maximum Plasma Concentration (Cmax) | 9.73 ± 20.44 | 9.97 ± 29.07 | 10.25 ± 26.87 | 10.88 ± 23.72 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC (0-inf) is the area under the plasma concentration-time curve from time zero extrapolated to infinite time.
| ng*hr/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Metformin PK Parameter AUC(0-inf) | 11998.00 ± 23.68 | 12271.61 ± 20.42 | 11988.30 ± 16.94 | 11838.11 ± 18.18 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Cmax is the maximum observed concentration of drug substance in plasma.
| ng/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Metformin PK Parameter Cmax | 1724.38 ± 25.49 | 1715.79 ± 23.59 | 1571.21 ± 15.64 | 1541.76 ± 17.45 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC\[0-t\] is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
| ng*hr/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| 5-hydroxy Saxagliptin PK Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC[0-t]) | 109.60 ± 25.81 | 110.61 ± 22.77 | 113.15 ± 26.53 | 117.04 ± 25.74 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.
| hr | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| 5-hydroxy Saxagliptin PK Parameter Terminal Half-life (T 1/2) | 7.58 ± 1.32 | 7.58 ± 1.35 | 7.48 ± 1.10 | 7.22 ± 1.01 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
| hr | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| 5-hydroxy Saxagliptin PK Parameter Time to Achieve the Observed Maximum Plasma Concentration (Tmax) | 2.21 ± 0.75 | 1.86 ± 0.71 | 2.65 ± 0.83 | 2.46 ± 0.72 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.
| participants | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Number of Participants With at Least 1 AE | 4 | 5 | 3 | 4 |
| Discontinuation Due to AE | 1 | 0 | 0 | 0 |
| Deaths | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
| ng*hr/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Saxagliptin PK Parameter AUC(0-t) | 47.15 ± 17.98 | 47.83 ± 19.77 | 50.69 ± 17.74 | 51.37 ± 17.63 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.
| hr | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Saxagliptin PK Parameter T1/2 | 6.45 ± 1.00 | 6.21 ± 1.25 | 5.86 ± 0.92 | 6.09 ± 0.94 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
| hr | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Saxagliptin PK Parameter Tmax | 1.38 ± 0.79 | 0.96 ± 0.61 | 1.94 ± 0.95 | 1.48 ± 0.58 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. AUC(0-t) is the area under the plasma concentration-time curve from time zero to time of last measurable concentration.
| ng*hr/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Metformin PK Parameter AUC(0-t) | 11826.52 ± 23.86 | 11875.08 ± 21.47 | 11796.60 ± 17.03 | 11681.05 ± 17.59 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. T 1/2 is the time required for the concentration of the drug to reach half of its original value in plasma.
| hr | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Metformin PK Parameter T1/2 | 10.94 ± 4.13 | 13.15 ± 6.67 | 10.82 ± 3.18 | 11.13 ± 3.08 |
PK is the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. Tmax is the time taken to reach the maximum observed plasma concentration.
| hr | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Metformin PK Parameter Tmax | 2.41 ± 0.78 | 2.54 ± 0.92 | 3.74 ± 0.54 | 3.74 ± 0.45 |
Abnormalities that were considered clinically significant and/or reported as an AE by the investigator.
| participants | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Clinical Laboratory Abnormalities | 0 | 0 | 1 | 0 |
| Vital Sign Abnormalities | 0 | 0 | 0 | 0 |
| Physical Examination Abnormalities | 0 | 0 | 0 | 0 |
| 12-Lead ECG Abnormalities | 0 | 0 | 0 | 0 |
Collected over AEs: from study drug administration Day 1/Period 1 till study discharge. SAEs: from date of written consent until 30 days after discontinuation of dosing or study participation. Duration of the study was approximately 45 days (including screening).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | — | 0/24 (0%) | 4/24 (16.7%) |
| Treatment B | — | 0/24 (0%) | 5/24 (20.8%) |
| Treatment C | — | 0/23 (0%) | 3/23 (13%) |
| Treatment D | — | 0/23 (0%) | 4/23 (17.4%) |
| Event | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/24 | 2/24 | 1/23 | 3/23 |
| Abdominal painGastrointestinal disorders | 2/24 | 1/24 | 0/23 | 1/23 |
| DizzinessNervous system disorders | 1/24 | 1/24 | 0/23 | 1/23 |
| NasopharyngitisInfections and infestations | 0/24 | 0/24 | 1/23 | 0/23 |
| FatigueGeneral disorders | 0/24 | 0/24 | 1/23 | 1/23 |
| Vision blurredEye disorders | 0/24 | 1/24 | 0/23 | 0/23 |
| HeadacheNervous system disorders | 1/24 | 0/24 | 0/23 | 0/23 |
| PresyncopeNervous system disorders | 0/24 | 1/24 | 0/23 | 0/23 |
| NauseaGastrointestinal disorders | 1/24 | 0/24 | 0/23 | 0/23 |
| Muscle strainInjury, poisoning and procedural complications | 1/24 | 0/24 | 0/23 | 0/23 |
| Age, Continuous(years) | All Enrolled and Treated Participants |
|---|---|
| Mean | 35.5 ± 10.61 |
| Sex: Female, Male(Participants) | All Enrolled and Treated Participants |
|---|---|
| Female | 8 |
| Male | 16 |
| Ethnicity (NIH/OMB)(Participants) | All Enrolled and Treated Participants |
|---|---|
| Hispanic or Latino | 11 |
| Not Hispanic or Latino | 13 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Enrolled and Treated Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 21 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | All Enrolled and Treated Participants |
|---|---|
| United States | 24 |
| Height(cm) | All Enrolled and Treated Participants |
|---|---|
| Mean | 170.2 ± 12.0 |
| Weight(kg) | All Enrolled and Treated Participants |
|---|---|
| Mean | 79.7 ± 13.7 |
| Body Mass Index (BMI)(kg/m^2) | All Enrolled and Treated Participants |
|---|---|
| Mean | 27.4 ± 3.05 |
The record gives a start of Feb 2010, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Metformin